• Published in Journal of Asthma – 2020

  • Collaborator: AstraZeneca

  • Authors: Dany Jaffuel, Caroline Fabry-Vendrand, Elsa Darnal, Ophélie Wilczynski, Emilie Pain & Arnaud Bourdin

Oral corticosteroids (OCS) are frequently used as relievers for acute asthma and controllers for severe asthma. However, the relief offered by OCS is counterbalanced by adverse effects.

Objective: The objective of this study was to describe how patients perceive OCS treatment benefits and risks, and how this could affect their adherence to the treatment.